title: Impaired hepatitis B vaccine responses during chronic hepatitis C infection: involvement of the PD-1 pathway in regulating CD4(+) T cell responses.
abstract: Vaccination for hepatitis B virus (HBV) in the setting of hepatitis C virus (HCV) infection is recommended, but responses to vaccination are blunted when compared to uninfected populations. The mechanism for this failure of immune response in HCV-infected subjects remains unknown but is thought to be a result of lymphocyte dysfunction during chronic viral infection. We have recently demonstrated that PD-1, a novel negative immunomodulator for T cell receptor (TCR) signaling, is involved in T and B lymphocyte dysregulation during chronic HCV infection. In this report, we further investigated the role of the PD-1 pathway in regulation of CD4(+) T cell responses to HBV vaccination in HCV-infected individuals. In a prospective HCV infected cohort, a poor response rate to HBV vaccination as assayed by seroconversion was observed in HCV-infected subjects (53%), while a high response rate was observed in healthy or spontaneously HCV-resolved individuals (94%). CD4(+) T cell responses to ex vivo stimulations of anti-CD3/CD28 antibodies or hepatitis B surface antigen (HBsAg) were found to be lower in HBV vaccine non-responders compared to those responders in HCV-infected individuals who had received a series of HBV immunizations. PD-1 expression on CD4(+) T cells was detected at relatively higher levels in these HBV vaccine non-responders than those who responded, and this was inversely associated with the cell activation status. Importantly, blocking the PD-1 pathway improved T cell activation and proliferation in response to ex vivo HBsAg or anti-CD3/CD28 stimulation in HBV vaccine non-responders. These results suggest that PD-1 signaling may be involved in impairing CD4(+) T cell responses to HBV vaccination in subjects with HCV infection, and raise the possibility that blocking this negative signaling pathway might improve success rates of immunization in the setting of chronic viral infection.
authors.affiliation: Medical Service, Department of Veterans Affairs, James H. Quillen VA Medical Center, Johnson City, TN 37614, USA. Moorman@etsu.edu
authors.forename: Jonathan P
authors.initials: JP
authors.lastname: Moorman
authors.forename: Chun L
authors.initials: CL
authors.lastname: Zhang
authors.forename: Lei
authors.initials: L
authors.lastname: Ni
authors.forename: Cheng J
authors.initials: CJ
authors.lastname: Ma
authors.forename: Ying
authors.initials: Y
authors.lastname: Zhang
authors.forename: Xiao Y
authors.initials: XY
authors.lastname: Wu
authors.forename: Penny
authors.initials: P
authors.lastname: Thayer
authors.forename: Tareq M
authors.initials: TM
authors.lastname: Islam
authors.forename: Thomas
authors.initials: T
authors.lastname: Borthwick
authors.forename: Zhi Q
authors.initials: ZQ
authors.lastname: Yao
mesh_terms: D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000378:metabolism*; D051017:Apoptosis Regulatory Proteins / Q000378:metabolism*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D049109:Cell Proliferation; D015331:Cohort Studies; D005260:Female; D020869:Gene Expression Profiling; D006514:Hepatitis B Surface Antigens / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology*; D019698:Hepatitis C, Chronic / Q000276:immunology*; D006801:Humans; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D061026:Programmed Cell Death 1 Receptor
chemical_list: D015703:Antigens, CD; D051017:Apoptosis Regulatory Proteins; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor